Free Trial
→ I'm handing you this one free (From Behind the Markets) (Ad)tc pixel
NASDAQ:IMTX

Immatics Q3 2026 Earnings Date & Estimates

Immatics logo
$7.12 -0.08 (-1.11%)
As of 01:46 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Immatics is estimated to report Q3 2026 earnings on Tuesday, November 17, 2026, before market opens. The conference call is scheduled for November 13, 2026 at 12:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
12:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Immatics in Q3 2026

Immatics is expected to post earnings of -$0.49 per share on revenue of $12.18 million. In the same quarter a year earlier Immatics reported -$0.49 per share on revenue of $6.10 million. Immatics last reported on August 18, 2026, posting -$0.53 per share and missing the -$0.4748 consensus estimate. Immatics has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.49
Expected Revenue
$12.18 million
Prior-Year EPS
-$0.49
Prior-Year Revenue
$6.10 million
Expected Revenue Growth
+99.7%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.53 (Missed by -$0.0552)
Last Quarter Revenue
$10.44 million
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

Immatics Q3 2026 Earnings FAQ

Immatics (NASDAQ:IMTX) is estimated to report Q3 2026 earnings on Tuesday, November 17, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Immatics' Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 12:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Immatics to post earnings of -$0.49 per share for Q3 2026.

The consensus revenue estimate for Immatics is $12.18 million for Q3 2026.

Immatics Earnings Headlines

Immatics (IMTX) PRAME Data Puts A Pricey Valuation Back In Focus
November 1 at 7:05 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/immatics-imtx-prame-data-puts-002103411.html
Immatics (IMTX) Stock Looks Stretched As PRAME Trial Data Impresses
October 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/immatics-imtx-stock-looks-stretched-010921914.html
Elon Musk about to bankrupt Amazon, Microsoft & Google?
Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracking a new Elon Musk project he calls the most epic AI initiative in history. The plan could give Musk access to 50 times more computing power than the rest of the world combined, a development Brown says is drawing attention from executives at Amazon, Microsoft, and Google. Brown compares the scale of this project to the SpaceX IPO, which minted thousands of millionaires overnight.tc pixel
November 2 at 1:00 AM  |  Brownstone Research (Ad)
Should Updated Trial Results Require Action From Immatics (IMTX) Investors?
October 25, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/updated-trial-results-require-action-032057405.html
Immatics N.V. Presents Updated Clinical Trial Data from Ongoing Phase 1B Study with IMA402 PRAME Bispecific and Phase 1 Study with IMA203CD8 PRAME Cell Therapy
October 24, 2026  |  marketscreener.comM
Immatics Reports Encouraging ESMO Data for IMA402 and IMA203CD8 Across Multiple PRAME-Positive Cancers
October 24, 2026  |  quiverquant.comQ
See More Immatics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immatics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immatics and other key companies, straight to your email.

About Immatics

Immatics (NASDAQ:IMTX) is a biotechnology company developing T cell receptor (TCR)-based immunotherapies for cancer. The company’s approach is designed to recognize cancer-associated targets presented on the surface of tumor cells and activate the immune system against malignant tissue.

Its research and development programs include TCR-engineered T cell therapies, TCR bispecific molecules and other cell-based immunotherapies. Immatics has developed technology platforms intended to identify tumor targets and generate therapeutic TCRs, supporting programs for both solid tumors and blood cancers. Its pipeline has included PRAME-directed therapies and other investigational candidates, which remain subject to clinical testing and regulatory review.

Founded in 2000 and headquartered in Tübingen, Germany, Immatics also maintains operations in the United States, including a presence in Houston, Texas. The company works with pharmaceutical and biotechnology partners to advance its immunotherapy programs and is listed on the Nasdaq Global Select Market under the symbol IMTX.

View Immatics Profile
Earnings Tools